2019
DOI: 10.24170/16-4-3844
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: The guideline is not context-specific and serves as a universal tool to facilitate clinical decision-making based on best practice evidence. (4,11) The guideline uses a riskstratification approach with a clinical algorithm, including a combination of developmental surveillance, screening and evaluation aimed at the early identification of developmental delays. (1,2,4,10) By extension, the successful implementation of the guideline also results in the appropriate referral of children with developmental delays t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
11
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(11 citation statements)
references
References 30 publications
(60 reference statements)
0
11
0
Order By: Relevance
“…The AHA 2012 statement has been instrumental in raising awareness of the complex structure and process that need to be put in place for the optimal monitoring of children with CHD and is regarded as the "gold standard" in various countries. 4,8,9 However, it remains unclear the extent to which these recommendations were implemented outside the United States and whether their implementation is feasible in other contexts. In countries with publicly funded health care systems, such as Canada, the absence of the medical home structure, on which the recommendations were based, may present a barrier to their implementation.…”
Section: R Esum Ementioning
confidence: 99%
“…The AHA 2012 statement has been instrumental in raising awareness of the complex structure and process that need to be put in place for the optimal monitoring of children with CHD and is regarded as the "gold standard" in various countries. 4,8,9 However, it remains unclear the extent to which these recommendations were implemented outside the United States and whether their implementation is feasible in other contexts. In countries with publicly funded health care systems, such as Canada, the absence of the medical home structure, on which the recommendations were based, may present a barrier to their implementation.…”
Section: R Esum Ementioning
confidence: 99%
“…The 35 publications included in the scoping review comprised 33 different studies. Of these, 21 studies examined the implementation of specific programmes or care pathways for neurodevelopmental follow‐up care, 27–29,31–36,38–40,42,44,47–54,56 and 12 studies reported on surveys or overviews of current clinical practices in neurodevelopmental follow‐up 9,13–16,30,37,41,43,45,46,55 …”
Section: Resultsmentioning
confidence: 99%
“…Of these, 21 studies examined the implementation of specific programmes or care pathways for neurodevelopmental follow-up care, [27][28][29][31][32][33][34][35][36][38][39][40]42,44,[47][48][49][50][51][52][53][54]56 and 12 studies reported on surveys or overviews of current clinical practices in neurodevelopmental follow-up. 9,[13][14][15][16]30,37,41,43,45,46,55 Implementation and evaluation of follow-up programmes or care pathways All studies were published after 2011, with most (15 out of 21) conducted since 2018. Fourteen of the studies reported on neurodevelopmental care pathways or programmes based in the USA, 27,[32][33][34][35][36][38][39][40]42,44,[46]…”
Section: Characteristics Of Included Studiesmentioning
confidence: 99%
See 2 more Smart Citations